[go: up one dir, main page]

CL2017001736A1 - Anti-CD47 antibodies and use thereof. - Google Patents

Anti-CD47 antibodies and use thereof.

Info

Publication number
CL2017001736A1
CL2017001736A1 CL2017001736A CL2017001736A CL2017001736A1 CL 2017001736 A1 CL2017001736 A1 CL 2017001736A1 CL 2017001736 A CL2017001736 A CL 2017001736A CL 2017001736 A CL2017001736 A CL 2017001736A CL 2017001736 A1 CL2017001736 A1 CL 2017001736A1
Authority
CL
Chile
Prior art keywords
methods
antibodies
prepare
compositions
diagnostic
Prior art date
Application number
CL2017001736A
Other languages
Spanish (es)
Inventor
Aaron Sato
Ryan Stafford
Junhao Yang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2017001736A1 publication Critical patent/CL2017001736A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>SE PROPORCIONAN AQUÍ COMPOSICIONES, MÉTODOS Y USOS QUE IMPLICAN ANTICUERPOS QUE SE UNEN ESPECÍFICAMENTE A CD47 HUMANO. TAMBIÉN SE PROPORCIONAN USOS Y MÉTODOS, TALES COMO MÉTODOS TERAPÉUTICOS, MÉTODOS DE DIAGNÓSTICO Y MÉTODOS PARA PREPARAR DICHOS ANTICUERPOS.</p><p> COMPOSITIONS, METHODS AND USES THAT INCLUDE ANTIBODIES THAT SPECIFICALLY JOIN HUMAN CD47 ARE PROVIDED HERE. USES AND METHODS ARE ALSO PROVIDED, SUCH AS THERAPEUTIC METHODS, DIAGNOSTIC METHODS AND METHODS TO PREPARE SUCH ANTIBODIES. </p>

CL2017001736A 2014-12-30 2017-06-29 Anti-CD47 antibodies and use thereof. CL2017001736A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098291P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
CL2017001736A1 true CL2017001736A1 (en) 2018-03-16

Family

ID=56284963

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001736A CL2017001736A1 (en) 2014-12-30 2017-06-29 Anti-CD47 antibodies and use thereof.

Country Status (17)

Country Link
US (2) US10870699B2 (en)
EP (1) EP3240569A4 (en)
JP (2) JP6850255B2 (en)
KR (1) KR102489471B1 (en)
CN (1) CN107530421B (en)
AU (1) AU2015374301B2 (en)
BR (1) BR112017014258A2 (en)
CA (1) CA2972604C (en)
CL (1) CL2017001736A1 (en)
CO (1) CO2017007673A2 (en)
EA (1) EA037654B1 (en)
EC (1) ECSP17041865A (en)
HK (1) HK1245154A1 (en)
MX (1) MX391051B (en)
SG (2) SG11201705310TA (en)
WO (1) WO2016109415A1 (en)
ZA (1) ZA201704467B (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391051B (en) 2014-12-30 2025-03-21 Celgene Corp ANTI-CD47 ANTIBODIES AND THEIR USES.
SG11201708334RA (en) * 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
JP7120989B2 (en) * 2016-07-06 2022-08-17 セルジーン コーポレイション Antibodies with low immunogenicity and uses thereof
CN109790215B (en) 2016-09-29 2023-06-30 北京韩美药品有限公司 Heterodimeric immunoglobulin constructs and methods for their preparation
JP7043074B2 (en) 2016-10-20 2022-03-29 アイ－マブ バイオファーマ ユーエス リミテッド New CD47 monoclonal antibody and its use
EP3534965A4 (en) 2016-11-03 2020-06-24 Trillium Therapeutics Inc. IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODIES
SG10201913260VA (en) 2016-11-18 2020-03-30 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
CN110461872B (en) * 2017-01-26 2023-09-26 再鼎医药(上海)有限公司 CD47 antigen binding units and uses thereof
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
WO2018183182A1 (en) * 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
US11203611B2 (en) 2017-04-14 2021-12-21 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
SG11202000053TA (en) 2017-08-02 2020-02-27 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
KR102781208B1 (en) 2017-08-18 2025-03-17 센테사 파마슈티칼스 (유케이) 리미티드 binder
KR102366853B1 (en) * 2017-11-10 2022-02-23 아이-맵 바이오파마 유에스 리미티드 Fusion protein comprising CD47 antibody and cytokine
US11180552B2 (en) 2017-12-01 2021-11-23 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
MX2020005792A (en) 2017-12-04 2020-11-06 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof.
KR20200116109A (en) * 2018-01-24 2020-10-08 난징 레전드 바이오테크 씨오., 엘티디. Anti-CD47 antibody that does not cause significant red blood cell aggregation
WO2019153200A1 (en) 2018-02-08 2019-08-15 北京韩美药品有限公司 Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (en) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 An antibody that blocks the interaction of CD47 and SIRPα
CN112566662A (en) * 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 Blocking antibodies against CD47 and methods of use thereof
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
CN110872348B (en) * 2018-09-03 2021-09-03 长春金赛药业有限责任公司 Humanized anti-CD 47 monoclonal antibody and application thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
MX2021010531A (en) * 2019-03-06 2021-10-01 Jiangsu Hengrui Medicine Co Bifunctional fusion protein and pharmaceutical use thereof.
TW202045550A (en) * 2019-04-05 2020-12-16 美商西建公司 Engineering of an antibody for tumor-selective binding of cd47
JP7561775B2 (en) 2019-06-07 2024-10-04 エーエルエックス オンコロジー インコーポレイテッド Methods and reagents for reducing interference of drugs that bind to CD47 in serological assays - Patents.com
JP7454645B2 (en) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド HIV vaccine and its production and use methods
CN112516301B (en) * 2019-09-17 2025-03-18 鲁南制药集团股份有限公司 A liquid preparation of CD47 monoclonal antibody and its preparation method
ES2973832T3 (en) 2019-10-18 2024-06-24 Forty Seven Inc Combination therapies for the treatment of myelodysplastic syndromes and acute myeloid leukemia
KR102866810B1 (en) * 2019-10-25 2025-09-30 우시 바이올로직스 아일랜드 리미티드 Novel anti-CD47 antibodies and their uses
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Diacylglycerol kinase modulating compounds
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
MX2022010515A (en) 2020-02-28 2022-11-14 Tallac Therapeutics Inc CONJUGATION MEDIATED BY TRANSGLUTAMINASE.
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023531678A (en) 2020-06-22 2023-07-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー TSP-1 inhibitors for the treatment of aged, atrophic, or dystrophic muscles
JP2023531537A (en) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ Use of leukemia-derived cells in ovarian cancer vaccines
JP7789304B2 (en) * 2020-07-31 2025-12-22 バイオ－テラ ソリュ－ションズ，エルティーディー． CD47 antibody and its applications
EP4211156A1 (en) * 2020-09-14 2023-07-19 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
CN116685348A (en) 2020-10-07 2023-09-01 细胞基因公司 Bispecific antibody treatment of lymphoid malignancy conditions
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN114656566B (en) * 2020-12-23 2023-09-22 广东菲鹏制药股份有限公司 An antibody targeting CD47 and its application
JP2024503822A (en) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Bispecific antibody targeting GPC3 and CD47
US20250277031A1 (en) * 2021-01-08 2025-09-04 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to cd47 and antigen-binding fragment thereof
AU2022235341A1 (en) 2021-03-12 2023-09-21 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
CN117355531A (en) 2021-06-23 2024-01-05 吉利德科学公司 Diacylglycerol kinase modulating compounds
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024539252A (en) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド Pyridin-3(2H)-one derivatives
PE20241186A1 (en) 2021-10-29 2024-06-03 Gilead Sciences Inc CD73 COMPOUNDS
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024546851A (en) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
PL4245756T3 (en) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (en) 2022-04-05 2025-03-11 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
CA3249472A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250304694A1 (en) * 2022-06-29 2025-10-02 Korea University Research And Business Foundation Glycosylated fc variants of which binding affinity for human fcgrs is removed
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
US20240010714A1 (en) * 2022-07-10 2024-01-11 Mbrace Therapeutics, Inc. Cell-free methods of recombinant antibody production
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
TW202440151A (en) 2022-12-09 2024-10-16 美商輝瑞大藥廠 Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
EP4630121A1 (en) 2022-12-09 2025-10-15 Pfizer Inc. Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy
CN120225509A (en) 2022-12-22 2025-06-27 吉利德科学公司 PRMT5 inhibitors and uses thereof
CN120882725A (en) 2023-04-11 2025-10-31 吉利德科学公司 KRAS-regulated compounds
KR20250175331A (en) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 PRMT5 inhibitors and uses thereof
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025179135A1 (en) * 2024-02-23 2025-08-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using targeted pore-forming agents
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1589107E (en) 1992-08-21 2010-03-29 Univ Bruxelles IMMUNOGLOBULINS FOR LIGHT CHAINS
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2331051T3 (en) 1999-11-29 2009-12-21 Bac Ip B.V. IMMOBILIZATION OF MOLECULES OF UNION OF ANTIGENS OF A DOMAIN.
JP2005538706A (en) 2001-07-12 2005-12-22 ジェファーソン フーテ， Super humanized antibody
DE102007001370A1 (en) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
EA018204B1 (en) * 2007-03-20 2013-06-28 Эли Лилли Энд Компани Anti-sclerostin antibodies
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011004847A1 (en) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 NOVEL HUMANIZED ANTI-HUMAN α9-INTEGRIN ANTIBODY
WO2011034969A1 (en) 2009-09-15 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
CN103635490A (en) * 2011-06-16 2014-03-12 诺瓦提斯公司 Soluble proteins for use as therapeutics
LT2804617T (en) * 2012-01-17 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University HIGH RELATED SIRP-ALPHA REAGENTS
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
CN111533804A (en) 2012-02-06 2020-08-14 印希彼有限公司 CD47 antibodies and methods of using the same
ES2944477T3 (en) * 2013-02-06 2023-06-21 Inhibrx Inc Non-Platelet Reducing and Non-Red Cell Reducing CD47 Antibodies and Methods of Using Them
US10190145B2 (en) * 2013-04-19 2019-01-29 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
MX391051B (en) 2014-12-30 2025-03-21 Celgene Corp ANTI-CD47 ANTIBODIES AND THEIR USES.
BR112018005322A2 (en) 2015-09-18 2018-12-11 Arch Oncology, Inc. monoclonal antibody or antigen-binding fragment thereof, pharmaceutical composition, monoclonal antibody or antigen-binding fragment thereof for use, method of treating ischemia-reperfusion injury, method of treating cancer in a human patient, method of evaluating expression CD47 into tumor and / or immune cells using a monoclonal antibody or antigen-binding fragment thereof
WO2017053423A1 (en) 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
JP2018506964A (en) 2018-03-15
CA2972604A1 (en) 2016-07-07
BR112017014258A2 (en) 2018-03-06
WO2016109415A1 (en) 2016-07-07
CA2972604C (en) 2023-07-04
EP3240569A4 (en) 2018-05-30
SG10202007176TA (en) 2020-08-28
US11787860B2 (en) 2023-10-17
KR20170100652A (en) 2017-09-04
MX2017008819A (en) 2018-03-14
CO2017007673A2 (en) 2018-01-05
MX391051B (en) 2025-03-21
US10870699B2 (en) 2020-12-22
HK1245154A1 (en) 2018-08-24
JP2021048858A (en) 2021-04-01
SG11201705310TA (en) 2017-07-28
JP6850255B2 (en) 2021-03-31
EA037654B1 (en) 2021-04-27
US20170369572A1 (en) 2017-12-28
ECSP17041865A (en) 2017-08-31
ZA201704467B (en) 2019-09-25
US20210054070A1 (en) 2021-02-25
EA201791485A1 (en) 2018-02-28
EP3240569A1 (en) 2017-11-08
CN107530421B (en) 2021-07-20
AU2015374301A1 (en) 2017-07-20
AU2015374301B2 (en) 2021-02-11
CN107530421A (en) 2018-01-02
KR102489471B1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
CL2017001736A1 (en) Anti-CD47 antibodies and use thereof.
MX385585B (en) ANTI-C10ORF54 ANTIBODIES AND THEIR USES.
IL261621A (en) Genome-edited vaccine activator cells
MX388350B (en) ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USING THE SAME.
PE20200617A1 (en) ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES, AND METHODS OF USE OF ANTI-CD39 ANTIBODIES
IL264454A (en) New preparations, uses and methods for their preparation
CL2016002252A1 (en) Anti-egfrviii antibodies and uses thereof
CL2016002055A1 (en) Use of 3-isoxazolidinone compounds as selective herbicides
AR109625A1 (en) PROTEINS OF UNION TO ANTIGENS (ABP) THAT SELECTLY JOIN TIGIT AND METHODS FOR THE USE OF THE SAME
CL2016002569A1 (en) Antibodies, pharmaceutical compositions and uses thereof
BR112016021626A2 (en) 5-substituted indazol-3-carboxamides and their preparation and use
UY34876A (en) ANTI-EGFR ANTIBODIES AND USES OF THE SAME
ME03037B (en) NATRIJUM (2R, 5S, 13AR) -7, 9-DIOKSO-10- ((2,4,6-TRIFLUOROBENZIL) CARBAMOIL) -2, 3, 4, 5, 7, 9, 13, 13A-OKTAHIDRO-2, 5-METANOPIRIDO [1 &#39;, 2&#39;: 4,5] PEREZ [2, 1-B] OKSAZEPIN-8-OLATE
BR112016030968A2 (en) pridopidine analogues, preparation and use of these
MX2016009555A (en) Binding proteins and methods of use thereof.
EP2989939A4 (en) CENTRIFUGE, CENTRIFUGE BODY AND SOFT CENTRIFUGE BLADE
NI201400079A (en) NEW PIRROL DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CO7061078A2 (en) Enediine compounds, conjugates thereof and their uses and methods
CL2017000506A1 (en) New anti-mfi2 antibodies and methods of use
MX2016016886A (en) Anti-axl antibodies.
MX2023006415A (en) ANTIBODIES, USES AND METHODS.
CO7020877A2 (en) Anti-asic1 antibodies and uses thereof
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
BR112016019868A2 (en) tatk-cdkl5 fusion proteins, compositions, formulations, and their use
GT201600252A (en) NAFTIRIDINADIONA DERIVATIVES